

Ref: MHL/Sec&Legal/2026-27/41

August 20, 2026

To,
BSE Limited
Scrip Code: 542650

National Stock Exchange of India Limited
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform that the Board of Directors of Metropolis Quality Solutions Private Limited (“MQSPL”), a wholly owned subsidiary of Metropolis Healthcare Limited (“the Company”), has today approved the offer and issuance of Optionally Convertible Redeemable Preference Shares (“OCRPS”).

Upon successful subscription to and subsequent conversion of these OCRPS into equity shares, MQSPL will cease to be a wholly owned subsidiary of the Company but will continue to remain a subsidiary of the Company.

The details as required under the SEBI Listing Regulations are provided in ‘**Annexure A**’ with this intimation.

You are requested to take the above information on record.

Thanking you,
Yours faithfully,

For Metropolis Healthcare Limited

Kamlesh C Kulkarni
Head – Legal & Secretarial

Encl: a/a



Annexure A

(Pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026)

Particulars	Details
The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	Metropolis Quality Solutions Private Limited ('MQSPL') is a private limited company incorporated on September 15, 2025, under the Indian Companies Act, 2013. MQSPL is yet to commence its business operations and hence has not contributed to the turnover, revenue, income, or net worth of the Company.
Date on which the agreement for sale has been entered into	Not applicable
The expected date of completion of sale/disposal	The conversion of Optionally Convertible Redeemable Preference Shares ("OCRPS") into equity shares (at a ratio of 1:1) is subject to the fulfilment of the terms and conditions attached to the issuance and will be executed in tranches. The overall timeline for the complete conversion is expected to be up to 6 years.
Consideration received from such sale/disposal	Offer and issuance of 10,000 OCRPS of face value of INR 10/- (Indian Rupees Ten only) each, at par, aggregating to INR 1,00,000/- (Indian Rupees One Lakh only).
Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	Dr. Puneet Kumar Nigam, former Chief Quality Officer of the Company, is the proposed allottee. He does not belong to the Promoter or Promoter Group of the Company.
Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	The transaction does not qualify as a related party transaction.
Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	Yes, the transaction is outside the scope of Scheme of Arrangement. The provisions of Regulation 37A of the SEBI Listing Regulations are not applicable for the proposed issuance.
Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not applicable

